The Future of Wellness and Healthcare
Swiss Life Sciences Group Plc was founded to capitalise on the flourishing and ever-evolving cannabis and cannabidiol (CBD) sectors, the fastest-growing opportunity in life sciences, wellness and healthcare today.
Paving the Way
Our vision is to become a globally trusted brand supplier of organic CBD and phytocannabinoid medical products, with production, manufacturing and certification across the EU. Our strategy is to carefully build SLSG into one of Europe’s largest seed-to-consumer, vertically integrated business models, through a series of strategic investments, joint ventures, mergers and acquisitions.
RESEARCH / CULTIVATE / PROCESS / ANALYSE / PACKAGE / DELIVER
6 Reasons We Invest
SLSG controls the entire life cycle of the product.
Investments owned by a UK PLC – underlying asset protection.
Accomplished and skilled management team.
Europe is the fastest-growing market for cannabis, CBD and phytocannabinoids.
There is a clearly defined business plan and exit strategy.
The market will grow by 400% by 2023 and is predicted to be worth $28 billion in the EU alone by 2028.
All Under One Roof
Our complete vertical integration ensures the highest quality control for all hemp CBD products: from farming and cultivation, through extraction and purification, product manufacturing and on-site laboratory testing, to bulk CBD distribution.
Harvest + Processing
Phytocannabinoid-rich hemp plants, grown indoors and outdoors from our genetics, producing high-grade phytocannabinoids.
Farming + Cultivation
Unique proprietary genetics provide customers with a competitive advantage: high CBD/low THC cultivator – never genetically modified.
Extraction + Purification
Material purification processes ensure maximum/complete control of THC levels, including THC removal.
Formulation + Development
In-house product development teams can create unique custom formulations with rigorous testing and clinical trials.
White-labelled products are formulated, tested, packaged, and shipped, ready to be sold directly to customers.
Our Own Brands
Retail brands across all sectors, including wellness, recreational smokeables, and medical CBD products.
A Challenge Overcome
The Current Situation
At the moment, there is no uniform licensing structure. For example, within the EU, producers need to adapt to local regulations; these even differing provincially in some countries.
Recently, however, CBD was categorised as a ‘Novel Food’ by the EU and the UK, bringing much-needed regulation to end-market products. We believe that up to 90% of products currently in the market will be unable to comply and meet the pharmaceutical-grade standards that this will entail.
In addition, many of the growers and manufacturers will not improve their existing supply chains to meet these regulations. They will simply fade away or be taken over (as is now happening in the Canadian and USA marketplace), leaving only the large-scale players in the market.
Fortunately, Switzerland has established a clearly defined legal system for the cultivation, processing and distribution of CBD and phytocannabinoid medical products. It has an admirably progressive vision and is also looking favourably towards future relaxation around recreational cannabis.
SLSG has the strategy, culture, structure and people to bridge this gap, both internationally and with pharmaceutical companies. With a ‘seed-to-consumer-products’ FULLY AUDITED, VERIFIED AND CERTIFIED SUPPLY CHAIN, we are one of the only global companies able to fulfil this new regulatory criterion.
Along with our strategic partners, we have developed a proprietary blockchain supply chain management system that puts us at the forefront of the new regulatory framework – and, most importantly, ahead of multiple existing companies.
SLSG and our group companies have designed and developed, from the ground up, pharmaceutical-specification cultivation, processing systems and product manufacturing, adhering with GMP and phytocannabinoid requirements.
In an industry that has faced criticism throughout its emergence, SLSG offers customers transparent and trustworthy raw materials and products, guaranteed by our blockchain technology. This means you’ll be able to track your products from seed to supply through our convenient mobile app.
This app allows you to view official, certified documentation for the product you sell. For your reassurance, this information is added to the public blockchain to verify all the finished product aspects at each stage of production.
In June 2019, the Centre for Medicinal Cannabis revealed that over a third of CBD oils tested in a third-party lab was found to be mislabelled.
This mislabelling most often referred to the stated levels of cannabinoids (including CBD) and other significant ingredients – some of which would make the product technically illegal in the UK.
Unlike many other brands currently available in the UK market, SLSG CBD provides customers like you with all the information they need to make a confident decision on the products they consume:
“We are committed to meeting all regulatory requirements and establishing that all Swiss Life Sciences Group products receive extensive quality control and are guaranteed for efficacy and safety.”
We pride ourselves as being one of the only CBD companies in the world to successfully meet and fulfil all cross-country regulatory requirements. These standards include: consistent testing to ensure the absence of heavy metals, microbiological species, insecticides, herbicides, pesticides and residual solvents. Testing also provides an accurate record of the exact levels of cannabinoids in each product.